Novartis drug Signifor® LAR shows superior efficacy in acromegaly patients not controlled on first generation somatostatin analogues

[PR Newswire] – EAST HANOVER, N.J., May 5, 2014 /PRNewswire/ — Novartis today presented results from a pivotal Phase III trial of investigational therapy Signifor ® LAR (pasireotide LAR; SOM230) in patients with acromegaly … more

View todays social media effects on NVS

View the latest stocks trending across Twitter. Click to view dashboard

See who Novartis is hiring next, click here to view